Thanks to Al Musella for bringing this to our attention.
https://virtualtrials.com/news3.cfm?item=6529 (Al's commentary)
https://www.nejm.org/doi/full/10.1056/NEJMoa1716435 (full study, HTML)
https://www.nejm.org/doi/pdf/10.1056/NEJMoa1716435 (PDF download)
Here, as in some other viral therapy/immune therapy trials, we're seeing a long tail of survivors, in this case 21% surviving to 2, 3, 4 and 5 years (all dose levels). This is comparable to DNX-2401 phase 1 trial, where 20% survived at 3 years, or Toca 511 + FC (13% alive at 3 years, all dose levels).
The most intriguing part of the study is the observation that some of the patients had dramatic responses to chemotherapy (including lomustine) after treatment with the modified poliovirus. The randomized phase 2 trial open now is testing poliovirus alone versus poliovirus + single course lomustine.
This trial is open and Duke, and soon to open at Massachusetts General, UCSF, and Boca Raton.